| r&d systems 产品目录--泽浩公司 |
| r&d systems 产品目录列表 page 4 >> 1 2 3 4 5 6 7 8 9 10 >>..more |
| 产品编号 |
产品描述 |
规格/包装 |
品牌 |
| 2910-ap-010 |
recombinant mouse alkaline phosphatase/alpl, cf (10 ug) |
10 ug |
r&d systems |
| 2914-ht-001g |
human holo-transferrin, cf (1 g) |
1 g |
r&d systems |
| 2914-ht-100mg |
human holo-transferrin, cf (100 mg) |
100 mg |
r&d systems |
| 2915-il-025 |
recombinant mouse il-19 (25 ug) |
25 ug |
r&d systems |
| 2915-il-025/cf |
recombinant mouse il-19, cf (25 ug) |
25 ug |
r&d systems |
| 2918-sd-050 |
recombinant human syndecan-4, cf (50 ug) |
50 ug |
r&d systems |
| 291-g1-050 |
recombinant human igf-i/igf-1, cf (50 ug) |
50 ug |
r&d systems |
| 291-g1-250 |
recombinant human igf-i/igf-1, cf (250 ug) |
250 ug |
r&d systems |
| 2926-bp-025 |
recombinant human bmp-10 (25 ug) |
25 ug |
r&d systems |
| 2926-bp-025/cf |
recombinant human bmp-10, cf (25 ug) |
25 ug |
r&d systems |
| 2929-tm-050 |
recombinant human tim-4, cf (50 ug) |
50 ug |
r&d systems |
| 292-g2-050 |
recombinant human igf-ii, cf (50 ug) |
50 ug |
r&d systems |
| 292-g2-250 |
recombinant human igf-ii, cf (250 ug) |
250 ug |
r&d systems |
| 2930-k2-050 |
recombinant mouse kirrel2, cf |
50 µg |
r&d systems |
| 2934-st-050 |
recombinant mouse sortilin, cf (50 ug) |
50 ug |
r&d systems |
| 2939-ca-010 |
recombinant human carbonic anhydrase vi, cf (10 ug) |
10 ug |
r&d systems |
| 293-ve-010 |
recombinant human vegf 165 (10 ug) |
10 ug |
r&d systems |
| 293-ve-010/cf |
recombinant human vegf 165, cf (10 ug) |
10 ug |
r&d systems |
| 293-ve-050 |
recombinant human vegf 165 (50 ug) |
50 ug |
r&d systems |
| 293-ve-050/cf |
recombinant human vegf 165, cf (50 ug) |
50 ug |
r&d systems |
| 2940-cm-050 |
recombinant human cmg-2, cf (50 ug) |
50 ug |
r&d systems |
| 2947-cl-050 |
recombinant human lsectin/clec4g, cf |
50 µg |
r&d systems |
| 2949-mc-050 |
recombinant mouse mimecan, cf (50 ug) |
50 ug |
r&d systems |
| 294-hg-005 |
recombinant human hgf (5 ug) |
5 ug |
r&d systems |
| 294-hg-005/cf |
recombinant human hgf, cf (5 ug) |
5 ug |
r&d systems |
| 294-hg-025 |
recombinant human hgf (25 ug) |
25 ug |
r&d systems |
| 294-hg-025/cf |
recombinant human hgf, cf (25 ug) |
25 ug |
r&d systems |
| 294-hgn-005 |
recombinant human hgf (ns0-expressed) (5 ug) |
5 ug |
r&d systems |
| 294-hgn-005/cf |
recombinant human hgf (ns0-expressed), cf (5 ug) |
5 ug |
r&d systems |
| 294-hgn-025 |
recombinant human hgf (ns0-expressed) (25 ug) |
25 ug |
r&d systems |
| 294-hgn-025/cf |
recombinant human hgf (ns0-expressed), cf (25 ug) |
25 ug |
r&d systems |
| 2955-f2-050 |
recombinant mouse osf-2/periostin, cf (50 ug) |
50 ug |
r&d systems |
| 2956-ma-050 |
recombinant mouse marco, cf |
50 µg |
r&d systems |
| 2956-ma-050 |
recombinant mouse marco, cf |
50 µg |
r&d systems |
| 295-om-010 |
recombinant human oncostatin m (osm) (10 ug) |
10 ug |
r&d systems |
| 295-om-010/cf |
recombinant human oncostatin m (osm), cf (10 ug) |
10 ug |
r&d systems |
| 295-om-050 |
recombinant human oncostatin m (osm) (50 ug) |
50 ug |
r&d systems |
| 295-om-050/cf |
recombinant human oncostatin m (osm), cf (50 ug) |
50 ug |
r&d systems |
| 2960-lr-025 |
recombinant mouse lrp-6, cf (25 ug) |
25 ug |
r&d systems |
| 2965-sd-050 |
recombinant human syndecan-2, cf (50 ug) |
50 ug |
r&d systems |
| 2967-mp-010 |
recombinant mouse mmp-7, cf (10 ug) |
10 ug |
r&d systems |
| 2968-se-010 |
recombinant mouse prostasin/prss8, cf (10 ug) |
10 ug |
r&d systems |
| 2969-su-020 |
recombinant mouse sulfamidase/sgsh, cf (20 ug) |
20 ug |
r&d systems |
| 296-hr-050 |
recombinant human nrg1-alpha/hrg1-alpha egf domain (50 ug) |
50 ug |
r&d systems |
| 296-hr-050/cf |
recombinant human nrg1-alpha/hrg1-alpha egf domain, cf (50 ug) |
50 ug |
r&d systems |
| 2970-zn-010 |
recombinant human aminopeptidase p1/xpnpep1, cf (10 ug) |
10 ug |
r&d systems |
| 2974-pi-010 |
recombinant human tfpi, cf (10 ug) |
10 ug |
r&d systems |
| 2975-pi-010 |
recombinant mouse tfpi, cf (10 ug) |
10 ug |
r&d systems |
| 2976-as-050 |
recombinant mouse bace-1, cf (50 ug) |
50 ug |
r&d systems |
| 2977-as-020 |
recombinant mouse bace-2, cf (20 ug) |
20 ug |
r&d systems |
| 2978-ad-010 |
recombinant mouse tace/adam17, cf (10 ug) |
10 ug |
r&d systems |
| 2979-pi-010 |
recombinant mouse serpin a1/alpha-1-antitrypsin, cf (10 ug) |
10 ug |
r&d systems |
| 297-vp-005 |
recombinant human vegf/plgf heterodimer (5 ug) |
5 ug |
r&d systems |
| 297-vp-005/cf |
recombinant human vegf/plgf heterodimer, cf (5 ug) |
5 ug |
r&d systems |
| 2980-pi-010 |
recombinant human serpin e2/pn1, cf (10 ug) |
10 ug |
r&d systems |
| 2984-se-010 |
recombinant human proprotein convertase 7/pcsk7, cf (10 ug) |
10 ug |
r&d systems |
| 2985-zn-010 |
recombinant mouse trh-degrading ectoenzyme/trhde, cf (10 ug) |
10 ug |
r&d systems |
| 298-vs-005 |
recombinant human vegf 121 (5 ug) |
5 ug |
r&d systems |
| 298-vs-005/cf |
recombinant human vegf 121, cf (5 ug) |
5 ug |
r&d systems |
| 298-vs-025 |
recombinant human vegf 121 (25 ug) |
25 ug |
r&d systems |
| 298-vs-025/cf |
recombinant human vegf 121, cf (25 ug) |
25 ug |
r&d systems |
| 299-lt-005 |
recombinant human latent tgf-beta 1 (5 ug) |
5 ug |
r&d systems |
| 299-lt-005/cf |
recombinant human latent tgf-beta 1, cf (5 ug) |
5 ug |
r&d systems |
| 299-lt-025 |
recombinant human latent tgf-beta 1 (25 ug) |
25 ug |
r&d systems |
| 299-lt-025/cf |
recombinant human latent tgf-beta 1, cf (25 ug) |
25 ug |
r&d systems |
| 2zh3925h |
human ror mab (clone h3925) |
100 ug |
r&d systems |
| 2zh4537h |
human vdr/nr1i1 mab (clone h4537) |
100 ug |
r&d systems |
| 2zh6437h |
human ror gamma/nr1f3 mab (clone h6437) |
100 ug |
r&d systems |
| 2zh6812h |
human err gamma/nr3b3 mab (clone h6812) |
100 ug |
r&d systems |
| 2zh7507h |
human androgen r/nr3c4 mab (clone h7507) |
100 ug |
r&d systems |
| 2zh7833h |
human ngfi-b gamma/nor-1/nr4a3 mab (clone h7833) |
100 ug |
r&d systems |
| 2zh8031h |
human gr/nr3c1 mab (clone h8031) |
100 ug |
r&d systems |
| 2zk8801h |
human lrh-1/nr5a2 mab (clone k8801) |
100 ug |
r&d systems |
| 2zk9218h |
human hnf-4 alpha 1-6/nr2a1 mab (clone k9218) |
100 ug |
r&d systems |
| 2zk9814h |
human sall1 mab (clone k9814) |
100 ug |
r&d systems |
| 2zppj0069h |
human pentraxin 3/tsg-14 mab (clone ppj0069) |
100 ug |
r&d systems |
| 2zppz0506h |
human er beta/nr3a2 mab (clone ppz0506) |
100 ug |
r&d systems |
| 3005-tr-050 |
recombinant mouse tlr3, cf (50 ug) |
50 ug |
r&d systems |
| 3006-wn-025 |
recombinant mouse wnt-5b (25 ug) |
25 ug |
r&d systems |
| 3006-wn-025/cf |
recombinant mouse wnt-5b, cf (25 ug) |
25 ug |
r&d systems |
| 3007-bt-050 |
recombinant mouse btla/fc chimera, cf |
50 µg |
r&d systems |
| 3007-bt-050 |
recombinant mouse btla/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 3008-wn-025 |
recombinant human wnt-7a (25 ug) |
25 ug |
r&d systems |
| 3008-wn-025/cf |
recombinant human wnt-7a, cf (25 ug) |
25 ug |
r&d systems |
| 3009-sk-050 |
recombinant human slitrk1, cf (50 ug) |
50 ug |
r&d systems |
| 3014-nr-025 |
recombinant human norrin, cf (25 ug) |
25 ug |
r&d systems |
| 3017-mn-050 |
recombinant human matrilin-3, cf (50 ug) |
50 ug |
r&d systems |
| 301-r3-025 |
recombinant human il-3 sr alpha (25 ug) |
25 ug |
r&d systems |
| 301-r3-025/cf |
recombinant human il-3 sr alpha, cf (25 ug) |
25 ug |
r&d systems |
| 302-b2-002 |
recombinant human tgf-beta 2 (2 ug) |
2 ug |
r&d systems |
| 302-b2-002/cf |
recombinant human tgf-beta 2, cf (2 ug) |
2 ug |
r&d systems |
| 302-b2-010 |
recombinant human tgf-beta 2 (10 ug) |
10 ug |
r&d systems |
| 302-b2-010/cf |
recombinant human tgf-beta 2, cf (10 ug) |
10 ug |
r&d systems |
| 3030-cn-025 |
recombinant human contactin-5, cf (25 ug) |
25 ug |
r&d systems |
| 3034-a1-100 |
recombinant mouse epha1, cf (100 ug) |
100 ug |
r&d systems |
| 3035-a2-100 |
recombinant human epha2, cf (100 ug) |
100 ug |
r&d systems |
| 3036-a5-100 |
recombinant human epha5, cf (100 ug) |
100 ug |
r&d systems |
| 3037-a5-100 |
recombinant mouse epha5, cf (100 ug) |
100 ug |
r&d systems |
| 3038-b4-100 |
recombinant human ephb4, cf (100 ug) |
100 ug |
r&d systems |
| 3039-ab-050 |
recombinant mouse ifn-alpha/beta r1, cf (50 ug) |
50 ug |
r&d systems |
| 303-cr-050 |
recombinant human cntf sr alpha (50 ug) |
50 ug |
r&d systems |
| 303-cr-050/cf |
recombinant human cntf sr alpha, cf (50 ug) |
50 ug |
r&d systems |
| 3044-mn-050 |
recombinant human matrilin-2 (50 ug) |
50 ug |
r&d systems |
| 3044-mn-050/cf |
recombinant human matrilin-2, cf (50 ug) |
50 ug |
r&d systems |
| 3046-mb-025 |
recombinant human ccl4l1/mip-1 beta isoform lag-1 (25 ug) |
25 ug |
r&d systems |
| 3046-mb-025/cf |
recombinant human ccl4l1/mip-1 beta isoform lag-1, cf (25 ug) |
25 ug |
r&d systems |
| 3047-cc-050 |
recombinant human coco (50 ug) |
50 ug |
r&d systems |
| 3047-cc-050/cf |
recombinant human coco, cf (50 ug) |
50 ug |
r&d systems |
| 3048-vg-025 |
recombinant human vg5q, cf (25 ug) |
25 ug |
r&d systems |
| 3049-ca-010 |
recombinant human carbonic anhydrase va, cf (10 ug) |
10 ug |
r&d systems |
| 304-b3-001 |
recombinant human tgf-beta 1.2 (1 ug) |
1 ug |
r&d systems |
| 304-b3-001/cf |
recombinant human tgf-beta 1.2, cf (1 ug) |
1 ug |
r&d systems |
| 3050-av-050 |
recombinant human integrin alpha v beta 3, cf |
50 µg |
r&d systems |
| 305-gr-050 |
recombinant human igf-i sr (histidine-tagged),(igf-1 sr), cf (50 ug) |
50 ug |
r&d systems |
| 3064-n3-050 |
recombinant human nectin-3, cf |
50 µg |
r&d systems |
| 3067-sr-050 |
recombinant mouse sorcs3, cf |
50 µg |
r&d systems |
| 3067-sr-050 |
recombinant mouse sorcs3, cf |
50 µg |
r&d systems |
| 306-ir-050 |
recombinant human il-7 r alpha/cd127/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 3074-th-050 |
recombinant human thrombospondin-1, cf (50 ug) |
50 ug |
r&d systems |
| 3076-rb-050 |
recombinant human robo3/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 307-er-050 |
recombinant human erythropoietin sr (50 ug) |
50 ug |
r&d systems |
| 307-er-050/cf |
recombinant human erythropoietin sr, cf (50 ug) |
50 ug |
r&d systems |
| 308-fk-005 |
recombinant human flt-3 ligand (5 ug) |
5 ug |
r&d systems |
| 308-fk-005/cf |
recombinant human flt-3 ligand, cf (5 ug) |
5 ug |
r&d systems |
| 308-fk-025 |
recombinant human flt-3 ligand (25 ug) |
25 ug |
r&d systems |
| 308-fk-025/cf |
recombinant human flt-3 ligand, cf (25 ug) |
25 ug |
r&d systems |
| 308-fkn-005 |
recombinant human flt-3 ligand (nso) (5 ug) |
5 ug |
r&d systems |
| 308-fkn-005/cf |
recombinant human flt-3 ligand, cf (5 ug) |
5 ug |
r&d systems |
| 308-fkn-025 |
recombinant human flt-3 ligand (nso) (25 ug) |
25 ug |
r&d systems |
| 308-fkn-025/cf |
recombinant human flt-3 ligand, cf (25 ug) |
25 ug |
r&d systems |
| 3095-se-010 |
recombinant human kallikrein 12, cf (10 ug) |
10 ug |
r&d systems |
| 3097-zn-020 |
thermolysin, cf (20 ug) |
20 ug |
r&d systems |
| 309-il-002 |
recombinant human il-12/il-23 p40 monomer (2 ug) |
2 ug |
r&d systems |
| 3104-po-050 |
recombinant mouse podocan, cf (50 ug) |
50 ug |
r&d systems |
| 3105-dk-010 |
recombinant mouse dkk-4 (10 ug) |
10 ug |
r&d systems |
| 3105-dk-010/cf |
recombinant mouse dkk-4, cf (10 ug) |
10 ug |
r&d systems |
| 3106-am-050 |
recombinant mouse amica/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 3107-rn-025 |
recombinant human relaxin-3 (25 ug) |
25 ug |
r&d systems |
| 3107-rn-025/cf |
recombinant human relaxin-3, cf (25 ug) |
25 ug |
r&d systems |
| 3114-dc-050 |
recombinant human dectin-2/clecsf10, cf |
50 µg |
r&d systems |
| 3114-dc-050 |
recombinant human dectin-2/clecsf10, cf (50 ug) |
50 ug |
r&d systems |
| 3130-cl-050 |
recombinant mouse cl-p1/colec12, cf (50 ug) |
50 ug |
r&d systems |
| 3134-cp-050 |
recombinant human comp, cf (50 ug) |
50 ug |
r&d systems |
| 3135-sp-025 |
recombinant human f-spondin (25 ug) |
25 ug |
r&d systems |
| 3135-sp-025/cf |
recombinant human f-spondin, cf (25 ug) |
25 ug |
r&d systems |
| 3136-rl-010 |
recombinant rat il-23 (10 ug) |
10 ug |
r&d systems |
| 3136-rl-010/cf |
recombinant rat il-23, cf (10 ug) |
10 ug |
r&d systems |
| 3137-pl-010 |
recombinant porcine il-5 (10 ug) |
10 ug |
r&d systems |
| 3137-pl-010/cf |
recombinant porcine il-5, cf (10 ug) |
10 ug |
r&d systems |
| 3138-gn-025/cf |
recombinant human granulysin, cf (25 ug) |
25 ug |
r&d systems |
| 3139-fb-025 |
recombinant mouse fgf basic (25 ug) |
25 ug |
r&d systems |
| 3139-fb-025/cf |
recombinant mouse fgf basic, cf (25 ug) |
25 ug |
r&d systems |
| 313-ti-100 |
recombinant human tie-2/fc chimera, cf (100 ug) |
100 ug |
r&d systems |
| 3140-me-050 |
recombinant human mepe, cf (50 ug) |
50 ug |
r&d systems |
| 3144-je-025 |
recombinant rat ccl2/je/mcp-1 (25 ug) |
25 ug |
r&d systems |
| 3144-je-025/cf |
recombinant rat ccl2/je/mcp-1, cf (25 ug) |
25 ug |
r&d systems |
| 3146-tm-050 |
recombinant human tlr4/md-2 (50 ug) |
50 ug |
r&d systems |
| 3146-tm-050/cf |
recombinant human tlr4/md-2, cf (50 ug) |
50 ug |
r&d systems |
| 3147-rb-050 |
recombinant human robo2/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 314-bp-010 |
recombinant human bmp-4 (10 ug) |
10 ug |
r&d systems |
| 314-bp-010/cf |
recombinant human bmp-4, cf (10 ug) |
10 ug |
r&d systems |
| 3154-st-050 |
recombinant human sortilin, cf (50 ug) |
50 ug |
r&d systems |
| 3155-rb-050 |
recombinant mouse robo3/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 3159-nn-050 |
recombinant mouse nephrin, cf |
50 µg |
r&d systems |
| 315-br-100 |
recombinant human bmpr-ia/alk-3/fc chimera (100 ug) |
100 ug |
r&d systems |
| 315-br-100/cf |
recombinant human bmpr-ia/alk-3/fc chimera, cf (100 ug) |
100 ug |
r&d systems |
| 3160-ca-020 |
recombinant human active calcineurin, cf |
20 µg |
r&d systems |
| 3160-ca-020 |
recombinant human active calcineurin, cf (20 ug) |
20 ug |
r&d systems |
| 316-il-002 |
recombinant human il-16 (2 ug) |
2 ug |
r&d systems |
| 316-il-002/cf |
recombinant human il-16, cf (2 ug) |
2 ug |
r&d systems |
| 316-il-025 |
recombinant human il-16 (25 ug) |
25 ug |
r&d systems |
| 316-il-025/cf |
recombinant human il-16, cf (25 ug) |
25 ug |
r&d systems |
| 3174-mp-250 |
recombinant human myeloperoxidase, cf |
250 µg |
r&d systems |
| 3174-mp-250 |
recombinant human myeloperoxidase, cf (250 ug) |
250 ug |
r&d systems |
| 3176-ca-010 |
recombinant human carbonic anhydrase vb, cf (10 ug) |
10 ug |
r&d systems |
| 3177-ca-050 |
recombinant human carbonic anhydrase vii, cf (50 ug) |
50 ug |
r&d systems |
| 3178-pa-010 |
recombinant mouse coagulation factor iii/tissue factor, cf (10 ug) |
10 ug |
r&d systems |
| 317-il-050 |
recombinant human il-17 (50 ug) |
50 ug |
r&d systems |
| 317-il-050/cf |
recombinant human il-17, cf (50 ug) |
50 ug |
r&d systems |
| 3188-at-001g |
human apo-transferrin, cf (1 g) |
1 g |
r&d systems |
| 3188-at-100mg |
human apo-transferrin, cf (100 mg) |
100 mg |
r&d systems |
| 3198-pi-010 |
recombinant human serpin d1/heparin cofactor ii, cf (10 ug) |
10 ug |
r&d systems |
| 319-fg-025 |
recombinant human fgf-17 (25 ug) |
25 ug |
r&d systems |
| 319-fg-025/cf |
recombinant human fgf-17, cf (25 ug) |
25 ug |
r&d systems |
| 3209-bp-010 |
recombinant human bmp-9 (10 ug) |
10 ug |
r&d systems |
| 3209-bp-010/cf |
recombinant human bmp-9, cf (10 ug) |
10 ug |
r&d systems |
| 320-eo-020 |
recombinant human ccl11/eotaxin (20 ug) |
20 ug |
r&d systems |
| 320-eo-020/cf |
recombinant human ccl11/eotaxin, cf (20 ug) |
20 ug |
r&d systems |
| 320-eo-100 |
recombinant human ccl11/eotaxin (100 ug) |
100 ug |
r&d systems |
| 320-eo-100/cf |
recombinant human ccl11/eotaxin, cf (100 ug) |
100 ug |
r&d systems |
| 3210-c-025 |
recombinant mouse ccl6/c10 (truncated, aa 42-116) (25 ug) |
25 ug |
r&d systems |
| 3210-c-025/cf |
recombinant mouse ccl6/c10 (truncated, aa 42-116), cf (25 ug) |
25 ug |
r&d systems |
| 3214-eg-100 |
recombinant rat egf (100 ug) |
100 ug |
r&d systems |
| 3214-eg-100/cf |
recombinant rat egf, cf (100 ug) |
100 ug |
r&d systems |
| 3215-mf-050 |
recombinant mouse cx3cl1/fractalkine (aa 29-102), cf (50 ug) |
50 ug |
r&d systems |
| 3216-rl-025 |
recombinant rhesus macaque il-12 (25 ug) |
25 ug |
r&d systems |
| 3216-rl-025/cf |
recombinant rhesus macaque il-12, cf (25 ug) |
25 ug |
r&d systems |
| 3217-mg-025 |
recombinant mouse ccl9/10mip-1 gamma (truncated) (25 ug) |
25 ug |
r&d systems |
| 3217-mg-025/cf |
recombinant mouse ccl9/10mip-1 gamma (truncated), cf (25 ug) |
25 ug |
r&d systems |
| 3218-nd-025 |
recombinant human nodal (25 ug) |
25 ug |
r&d systems |
| 3218-nd-025/cf |
recombinant human nodal, cf (25 ug) |
25 ug |
r&d systems |
| 321-fl-050 |
recombinant human vegf r1/flt-1/fc chimera (50 ug) |
50 ug |
r&d systems |
| 321-fl-050/cf |
recombinant human vegf r1/flt-1/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 3220-zn-010 |
recombinant human meprin alpha subunit/mep1a, cf (10 ug) |
10 ug |
r&d systems |
| 3225-fn-100 |
recombinant human fibronectin fragment 2, cf (100 ug) |
100 ug |
r&d systems |
| 3229-bm-010 |
recombinant human bmp-2/bmp-7 heterodimer (10 ug) |
10 ug |
r&d systems |
| 3229-bm-010/cf |
recombinant human bmp-2/bmp-7 heterodimer, cf (10 ug) |
10 ug |
r&d systems |
| 322-pr-050 |
recombinant human pdgf sr alpha (50 ug) |
50 ug |
r&d systems |
| 322-pr-050/cf |
recombinant human pdgf sr alpha, cf (50 ug) |
50 ug |
r&d systems |
| 3230-a5-050 |
recombinant human integrin alpha 5 beta 1, cf (50 ug) |
50 ug |
r&d systems |
| 3234-mn-050 |
recombinant mouse matrilin-2 (50 ug) |
50 ug |
r&d systems |
| 3234-mn-050/cf |
recombinant mouse matrilin-2, cf (50 ug) |
50 ug |
r&d systems |
| 3235-nf-050 |
recombinant rat neurofascin, cf (50 ug) |
50 ug |
r&d systems |
| 3236-n4-005 |
recombinant mouse nt-4 (5 ug) |
5 ug |
r&d systems |
| 3236-n4-005/cf |
recombinant mouse nt-4, cf (5 ug) |
5 ug |
r&d systems |
| 3237-s3-025 |
recombinant mouse semaphorin 3f/fc chimera (truncated), cf (25 ug) |
25 ug |
r&d systems |
| 3238-s3-025 |
recombinant mouse semaphorin 3e/fc chimera, cf (25 ug) |
25 ug |
r&d systems |
| 3239-s3-025 |
recombinant human semaphorin 3e, cf (25 ug) |
25 ug |
r&d systems |
| 3245-mp-010 |
recombinant rat mmp-8, cf (10 ug) |
10 ug |
r&d systems |
| 3246-pi-010 |
recombinant human latexin, cf (10 ug) |
10 ug |
r&d systems |
| 324-hc-010 |
recombinant human ccl14a/hcc-1 (10 ug) |
10 ug |
r&d systems |
| 324-hc-010/cf |
recombinant human ccl14a/hcc-1, cf (10 ug) |
10 ug |
r&d systems |
| 324-hc-050 |
recombinant human ccl14a/hcc-1 (50 ug) |
50 ug |
r&d systems |
| 324-hc-050/cf |
recombinant human ccl14a/hcc-1, cf (50 ug) |
50 ug |
r&d systems |
| 3257-rn-025 |
recombinant human relaxin-1 (25 ug) |
25 ug |
r&d systems |
| 3257-rn-025/cf |
recombinant human relaxin-1, cf (25 ug) |
25 ug |
r&d systems |
| 3258-sl-050 |
recombinant human siglec-11/fc chimera,cf (50 ug) |
50 ug |
r&d systems |
| 325-ct-200 |
recombinant human ctla-4/fc chimera (200 ug) |
200 ug |
r&d systems |
| 325-ct-200/cf |
recombinant human ctla-4/fc chimera, cf (200 ug) |
200 ug |
r&d systems |
| 326-fs-050 |
recombinant human fas/tnfrsf6/fc chimera (50 ug) |
50 ug |
r&d systems |
| 326-fs-050/cf |
recombinant human fas (cd95)/tnfrsf6/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 327-p4-025 |
recombinant human ccl13/mcp-4 (25 ug) |
25 ug |
r&d systems |
| 327-p4-025/cf |
recombinant human ccl13/mcp-4, cf (25 ug) |
25 ug |
r&d systems |
| 329-mr-100 |
recombinant human m-csf r/fc chimera (100 ug) |
100 ug |
r&d systems |
| 329-mr-100/cf |
recombinant human m-csf r/fc chimera, cf (100 ug) |
100 ug |
r&d systems |
| 3300-zn-010 |
recombinant mouse meprin beta subunit/mep1b, cf (10 ug) |
10 ug |
r&d systems |
| 3305-se-010 |
recombinant mouse coagulation factor vii, cf (10 ug) |
10 ug |
r&d systems |
| 3308-ad-050 |
recombinant mouse osteoadherin, cf (50 ug) |
50 ug |
r&d systems |
| 3326-sr-050 |
recombinant human sorcs3, cf |
50 µg |
r&d systems |
| 3327-cd-050 |
recombinant mouse cd48/slamf2 (histidine-tagged), cf (50 ug) |
50 ug |
r&d systems |
| 332-sr-050 |
recombinant human scf sr/c-kit (50 ug) |
50 ug |
r&d systems |
| 332-sr-050/cf |
recombinant human scf sr/c-kit, cf (50 ug) |
50 ug |
r&d systems |
| 3339-fb-025 |
recombinant rat fgf basic (25 ug) |
25 ug |
r&d systems |
| 3339-fb-025/cf |
recombinant rat fgf basic, cf (25 ug) |
25 ug |
r&d systems |
| 333-gc-025 |
recombinant human cxcl6/gcp-2 (25 ug) |
25 ug |
r&d systems |
| 333-gc-025/cf |
recombinant human cxcl6/gcp-2, cf (25 ug) |
25 ug |
r&d systems |
| 3340-el-010 |
recombinant equine il-1 beta/il-1f2 (10 ug) |
10 ug |
r&d systems |
| 3340-el-010/cf |
recombinant equine il-1 beta/il-1f2, cf (10 ug) |
10 ug |
r&d systems |
| 3344-ng-050 |
recombinant human noggin/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 3345-ps-050 |
recombinant human psgl-1/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 3349-se-010 |
recombinant human coagulation factor xiv/protein c, cf (10 ug) |
10 ug |
r&d systems |
| 334-tk-025 |
recombinant human ccl25/teck (25 ug) |
25 ug |
r&d systems |
| 334-tk-025/cf |
recombinant human ccl25/teck, cf (25 ug) |
25 ug |
r&d systems |
| 3355-cd-050 |
recombinant mouse cd200/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 3356-cc-025 |
recombinant mouse coco |
25 µg |
r&d systems |
| 3356-cc-025/cf |
recombinant mouse coco, cf |
25 µg |
r&d systems |
| 3357-mn-050 |
recombinant mouse matrilin-3, cf |
50 µg |
r&d systems |
| 3357-mn-050 |
recombinant mouse matrilin-3, cf (50 ug) |
50 ug |
r&d systems |
| 335-rm-025 |
recombinant human ccl5/met-rantes (25 ug) |
25 ug |
r&d systems |
| 335-rm-025/cf |
recombinant human ccl5/met-rantes, cf (25 ug) |
25 ug |
r&d systems |
| 336-md-025 |
recombinant human ccl22/mdc (25 ug) |
25 ug |
r&d systems |
| 336-md-025/cf |
recombinant human ccl22/mdc, cf (25 ug) |
25 ug |
r&d systems |
| 3378-lc-050 |
recombinant human rbp4, cf (50 ug) |
50 ug |
r&d systems |
| 3380-mn-050 |
recombinant mouse matrilin-4, cf (50 ug) |
50 ug |
r&d systems |
| 3384-b6-200 |
recombinant human ephb6/fc chimera, cf (200 ug) |
200 ug |
r&d systems |
| 3385-nd-050 |
recombinant human nidogen-2, cf (50 ug) |
50 ug |
r&d systems |
| 3386-hg-025 |
recombinant canine hgf (25 ug) |
25 ug |
r&d systems |
| 3386-hg-025/cf |
recombinant canine hgf, cf (25 ug) |
25 ug |
r&d systems |
| 3387-pc-050 |
recombinant porcine cd31 (pecam-1), cf (50 ug) |
50 ug |
r&d systems |
| 3388-ox-050 |
recombinant human ox40 tnfrsf4/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 338-ac-005 |
recombinant human/mouse/rat activin a (5 ug) |
5 ug |
r&d systems |
| 338-ac-005/cf |
recombinant human/mouse/rat activin a, cf (5 ug) |
5 ug |
r&d systems |
| 338-ac-025 |
recombinant human/mouse/rat activin a (25 ug) |
25 ug |
r&d systems |
| 338-ac-025/cf |
recombinant human/mouse/rat activin a, cf (25 ug) |
25 ug |
r&d systems |
| 339-rb-100 |
recombinant human activin riib/fc chimera (ns0) (100 ug) |
100 ug |
r&d systems |
| 339-rb-100/cf |
recombinant human activin riib/fc chimera (ns0), cf (100 ug) |
100 ug |
r&d systems |
| 339-rbb-100 |
recombinant human activin riib/fc chimera (sf 21), cf (100 ug) |
100 ug |
r&d systems |
| 3409-bg-050 |
recombinant human beta ig-h3, cf (50 ug) |
50 ug |
r&d systems |
| 340-r2-100 |
recombinant human activin riia/fc chimera (100 ug) |
100 ug |
r&d systems |
| 340-r2-100/cf |
recombinant human activin riia/fc chimera, cf (100 ug) |
100 ug |
r&d systems |
| 3410-ur-050 |
recombinant human urb, cf (50 ug) |
50 ug |
r&d systems |
| 3414-cd-050 |
recombinant human cd200 r1/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 341-br-050 |
recombinant human tgf-beta rii/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 342-cd-200 |
recombinant human cd28/fc chimera, cf (200 ug) |
200 ug |
r&d systems |
| 3431-005-02 |
cultrex pathclear bme reduced growth factor - phenol red |
5 ml |
r&d systems |
| 3431-005-02 |
cultrex pathclear bme reduced growth factor - phenol red |
5 ml |
r&d systems |
| 3431-010-02 |
cultrex pathclear bme reduced growth factor - phenol red |
10 ml |
r&d systems |
| 3431-010-02 |
cultrex pathclear bme reduced growth factor - phenol red |
10 ml |
r&d systems |
| 3433-005-02 |
cultrex pathclear bme reduced growth factor |
5 ml |
r&d systems |
| 3433-010-02 |
cultrex pathclear bme reduced growth factor (2 x 5 ml) |
10 ml |
r&d systems |
| 3436-se-010 |
recombinant mouse dpp7, cf (10 ug) |
10 ug |
r&d systems |
| 3437-zn-010 |
recombinant mouse ace-2, cf (10 ug) |
10 ug |
r&d systems |
| 3438-se-010 |
recombinant human dpp7, cf (10 ug) |
10 ug |
r&d systems |
| 3439-zn-010 |
recombinant human thop1, cf (10 ug) |
10 ug |
r&d systems |
| 343-e2-025 |
recombinant human ccl24/eotaxin-2/mpif-2 (25 ug) |
25 ug |
r&d systems |
| 343-e2-025/cf |
recombinant human ccl24/eotaxin-2/mpif-2, cf (25 ug) |
25 ug |
r&d systems |
| 3449-am-050 |
recombinant human amica/fc chimera, cf |
50 µg |
r&d systems |
| 344-er-050 |
recombinant human egf r/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 3457-sr-050 |
recombinant human sorcs1, cf |
50 µg |
r&d systems |
| 3459-fz-050 |
recombinant human frizzled-10/fc chimera, cf |
50 µg |
r&d systems |
| 345-fg-025 |
recombinant human fgf-10 (25 ug) |
25 ug |
r&d systems |
| 345-fg-025/cf |
recombinant human fgf-10, cf (25 ug) |
25 ug |
r&d systems |
| 3466-pi-010 |
recombinant human app/protease nexin ii, cf (10 ug) |
10 ug |
r&d systems |
| 3467-mp-010 |
recombinant mouse mmp-12, cf (10 ug) |
10 ug |
r&d systems |
| 346-e3-025 |
recombinant human ccl26/eotaxin-3 (aa 24-94) (25 ug) |
25 ug |
r&d systems |
| 346-e3-025/cf |
recombinant human ccl26/eotaxin-3 (aa 24-94), cf (25 ug) |
25 ug |
r&d systems |
| 3476-lc-050 |
recombinant mouse rbp4, cf (50 ug) |
50 ug |
r&d systems |
| 347-dr-100 |
recombinant human trail r1/tnfrsf10a/fc chimera (100 ug) |
100 ug |
r&d systems |
| 347-dr-100/cf |
recombinant human trail r1/tnfrsf10a/fc chimera, cf (100 ug) |
100 ug |
r&d systems |
| 3485-an-050 |
recombinant human angiopoietin-like 4, cf (50 ug) |
50 ug |
r&d systems |
| 348-rb-050 |
recombinant human erbb3/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 3495-lr-050 |
recombinant human lrig3, cf (50 ug) |
50 ug |
r&d systems |
| 3497-nr-025 |
recombinant mouse norrin (25 ug) |
25 ug |
r&d systems |
| 3497-nr-025/cf |
recombinant mouse norrin, cf (25 ug) |
25 ug |
r&d systems |
| 349-f4-050 |
recombinant human vegf r3/flt-4/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 3508-lc-050 |
recombinant rat lipocalin-2/ngal, cf (50 ug) |
50 ug |
r&d systems |
| 350-ns-010/cf |
recombinant human/rhesus macaque/feline cxcl12/sdf-1a, cf (10 ug) |
10 ug |
r&d systems |
| 350-ns-050/cf |
recombinant human/rhesus macaque/feline cxcl12/sdf-1a, cf (50 ug) |
50 ug |
r&d systems |
| 3514-2b-050 |
recombinant mouse 2b4/cd244/slamf4/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 3515-ng-050 |
recombinant human nogo-a (aa 566-748)/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 3516-fl-050 |
recombinant human vegf r1/flt-1 (aa 27-328)/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 3519-s4-050 |
recombinant human igsf4, cf (50 ug) |
50 ug |
r&d systems |
| 351-fs-010 |
recombinant human/feline cxcl12/sdf-1 beta (aa 22-93) (10 ug) |
10 ug |
r&d systems |
| 351-fs-010/cf |
recombinant human/feline cxcl12/sdf-1 beta (aa 22-93), cf (10 ug) |
10 ug |
r&d systems |
| 351-fs-050 |
recombinant human/feline cxcl12/sdf-1 beta (aa 22-93) (50 ug) |
50 ug |
r&d systems |
| 351-fs-050/cf |
recombinant human/feline cxcl12/sdf-1 beta (aa 22-93), cf (50 ug) |
50 ug |
r&d systems |
| 3520-ar-050 |
recombinant human apolipoprotein e r2, cf |
50 µg |
r&d systems |
| 3520-ar-050 |
recombinant human apolipoprotein e r2, cf |
50 µg |
r&d systems |
| 3525-pr-050 |
recombinant mouse pilr-beta, cf |
50 µg |
r&d systems |
| 352-ms-010 |
recombinant human msp (10 ug) |
10 ug |
r&d systems |
| 352-ms-010/cf |
recombinant human msp, cf (10 ug) |
10 ug |
r&d systems |
| 352-ms-050 |
recombinant human msp (50 ug) |
50 ug |
r&d systems |
| 352-ms-050/cf |
recombinant human msp, cf (50 ug) |
50 ug |
r&d systems |
| 3537-zn-010 |
recombinant human methionine aminopeptidase 1, cf (10 ug) |
10 ug |
r&d systems |
| 3548-f2-050 |
recombinant human osf-2/periostin, cf (50 ug) |
50 ug |
r&d systems |
| 354-bp-010 |
recombinant human bmp-7 (10 ug) |
10 ug |
r&d systems |
| 354-bp-010/cf |
recombinant human bmp-7, cf (10 ug) |
10 ug |
r&d systems |
| 3557-ah-010 |
recombinant human asah2, cf |
10 µg |
r&d systems |
| 3557-ah-010 |
recombinant human asah2, cf (10 ug) |
10 ug |
r&d systems |
| 3558-ah-010 |
recombinant mouse asah2, cf (10 ug) |
10 ug |
r&d systems |
| 3559-gh-010 |
recombinant human chitotriosidase/chit1, cf (10 ug) |
10 ug |
r&d systems |
| 355-bec-010 |
recombinant human bmp-2 (e. coli-expressed) (10 ug) |
10 ug |
r&d systems |
| 355-bec-010/cf |
recombinant human bmp-2 (e. coli-expressed), cf (10 ug) |
10 ug |
r&d systems |
| 355-bm-010 |
recombinant human bmp-2 (10 ug) |
10 ug |
r&d systems |
| 355-bm-010/cf |
recombinant human bmp-2, cf (10 ug) |
10 ug |
r&d systems |
| 3560-zn-010 |
recombinant human cytosol nonspecific dipeptidase/cndp2, cf (10 ug) |
10 ug |
r&d systems |
| 3564-dc-010 |
recombinant human dopa decarboxylase/ddc, cf (10 ug) |
10 ug |
r&d systems |
| 3565-se-010 |
recombinant mouse trypsin 3/prss3, cf (10 ug) |
10 ug |
r&d systems |
| 356-hv-100 |
recombinant human hvem/tnfrsf14/fc chimera (100 ug) |
100 ug |
r&d systems |
| 356-hv-100/cf |
recombinant human hvem/tnfrsf14/fc chimera, cf (100 ug) |
100 ug |
r&d systems |
| 357-kd-050 |
recombinant human vegf r2/kdr/fc chimera (50 ug) |
50 ug |
r&d systems |
| 357-kd-050/cf |
recombinant human vegf r2/kdr/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 3586-se-010 |
recombinant human trypsin 2/prss2, cf (10 ug) |
10 ug |
r&d systems |
| 3587-zn-010 |
recombinant human carboxypeptidase e/cpe, cf (10 ug) |
10 ug |
r&d systems |
| 3589-ca-100 |
recombinant human cyclophilin a (aa 1-165), cf (100 ug) |
100 ug |
r&d systems |
| 358-mt-100 |
recombinant human hgf r/c-met/fc chimera (100 ug) |
100 ug |
r&d systems |
| 358-mt-100/cf |
recombinant human hgf r/c-met/fc chimera, cf (100 ug) |
100 ug |
r&d systems |
| 3596-rn-025 |
recombinant human relaxin-2 (25 ug) |
25 ug |
r&d systems |
| 3596-rn-025/cf |
recombinant human relaxin-2, cf (25 ug) |
25 ug |
r&d systems |
| 3597-rg-050 |
recombinant mouse rgm-b, cf (50 ug) |
50 ug |
r&d systems |
| 359-ea-200 |
recombinant human ephrin-a3/fc chimera, cf (200 ug) |
200 ug |
r&d systems |
| 360-mp-025 |
recombinant human ccl20/mip-3 alpha (25 ug) |
25 ug |
r&d systems |
| 360-mp-025/cf |
recombinant human ccl20/mip-3 alpha, cf (25 ug) |
25 ug |
r&d systems |
| 361-mi-025 |
recombinant human ccl19/mip-3 beta (25 ug) |
25 ug |
r&d systems |
| 361-mi-025/cf |
recombinant human ccl19/mip-3 beta, cf (25 ug) |
25 ug |
r&d systems |
| 3620-pi-010 |
recombinant mouse latexin, cf (10 ug) |
10 ug |
r&d systems |
| 3624-fn-050 |
recombinant human fibronectin fragment 4, cf (50 ug) |
50 ug |
r&d systems |
| 3625-il-010 |
recombinant human il-33 (10 ug) |
10 ug |
r&d systems |
| 3625-il-010/cf |
recombinant human il-33, cf (10 ug) |
10 ug |
r&d systems |
| 3626-ml-010 |
recombinant mouse il-33 (10 ug) |
10 ug |
r&d systems |
| 3626-ml-010/cf |
recombinant mouse il-33, cf (10 ug) |
10 ug |
r&d systems |
| 3627-gp-050 |
recombinant human gpvi, cf (50 ug) |
50 ug |
r&d systems |
| 3628-pc-050 |
recombinant mouse cd31/pecam-1, cf (50 ug) |
50 ug |
r&d systems |
| 3629-sl-050 |
recombinant mouse slit3, cf (50 ug) |
50 ug |
r&d systems |
| 362-cx-025 |
recombinant human cx3cl1/fractalkine (chemokine domain) (25 ug) |
25 ug |
r&d systems |
| 362-cx-025/cf |
recombinant human cx3cl1/fractalkine (chemokine domain), cf (25 ug) |
25 ug |
r&d systems |
| 3630-rg-050 |
recombinant human rgm-b, cf (50 ug) |
50 ug |
r&d systems |
| 3634-rg-050 |
recombinant mouse rgm-c, cf (50 ug) |
50 ug |
r&d systems |
| 3636-cm-050 |
recombinant mouse cmg-2 (50 ug) |
50 ug |
r&d systems |
| 3636-cm-050/cf |
recombinant mouse cmg-2, cf (50 ug) |
50 ug |
r&d systems |
| 363-mg-025 |
recombinant human ccl15/mip-1 delta/lkn-1 (92 aa) (25 ug) |
25 ug |
r&d systems |
| 363-mg-025/cf |
recombinant human ccl15/mip-1 delta/lkn-1 (92 aa), cf (25 ug) |
25 ug |
r&d systems |
| 3644-cd-050 |
recombinant human cd48/slamf2, cf (50 ug) |
50 ug |
r&d systems |
| 3645-s2-025 |
recombinant human stabilin-2 (aa 2198-2295) |
25 µg |
r&d systems |
| 3645-s2-025 |
recombinant human stabilin-2 (aa 2198-2295) (25 ug) |
25 ug |
r&d systems |
| 3645-s2-025/cf |
recombinant human stabilin-2 (aa 2198-2295), cf |
25 µg |
r&d systems |
| 3645-s2-025/cf |
recombinant human stabilin-2 (aa 2198-2295), cf (25 ug) |
25 ug |
r&d systems |
| 3647-tk-050 |
recombinant human notch-1/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 364-dn-025 |
recombinant human ccl17/tarc (25 ug) |
25 ug |
r&d systems |
| 364-dn-025/cf |
recombinant human ccl17/tarc, cf (25 ug) |
25 ug |
r&d systems |
| 365-fr-025 |
recombinant human cx3cl1/fractalkine (full length) (25 ug) |
25 ug |
r&d systems |
| 365-fr-025/cf |
recombinant human cx3cl1/fractalkine (full length), cf (25 ug) |
25 ug |
r&d systems |
| 3660-cd-050 |
recombinant human cd44/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 366-6c-025 |
recombinant human ccl21/6ckine (25 ug) |
25 ug |
r&d systems |
| 366-6c-025/cf |
recombinant human ccl21/6ckine, cf (25 ug) |
25 ug |
r&d systems |
| 3678-s4-050 |
recombinant human igsf4b, cf |
50 µg |
r&d systems |
| 367-nr-050 |
recombinant human ngf r/tnfrsf16/fc chimera (50 ug) |
50 ug |
r&d systems |
| 367-nr-050/cf |
recombinant human ngf r/tnfrsf16/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 3687-cr-050 |
recombinant mouse crtam/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 3688-lr-050 |
recombinant mouse lrig1, cf (50 ug) |
50 ug |
r&d systems |
| 3689-tm-050 |
recombinant rat tim-1/kim-1/havcr, cf (50 ug) |
50 ug |
r&d systems |
| 368-st-050 |
recombinant human flt-3/flk-2/fc chimera (50 ug) |
50 ug |
r&d systems |
| 368-st-050/cf |
recombinant human flt-3/flk-2/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 369-ea-200 |
recombinant human ephrin-a4/fc chimera, cf (200 ug) |
200 ug |
r&d systems |
| 370-al-100 |
recombinant human alk-1/fc chimera, cf (100 ug) |
100 ug |
r&d systems |
| 3710-se-010 |
recombinant human trypsin 3/prss3, cf (10 ug) |
10 ug |
r&d systems |
| 3714-se-010 |
recombinant human active trypsin 3/prss3, cf (10 ug) |
10 ug |
r&d systems |
| 3715-se-010 |
recombinant human fap, cf (10 ug) |
10 ug |
r&d systems |
| 3718-fb-01m |
recombinant human fgf basic (145 aa), cf (1 mg) |
1 mg |
r&d systems |
| 371-mp-025 |
recombinant human ccl23/mpif-1 (25 ug) |
25 ug |
r&d systems |
| 371-mp-025/cf |
recombinant human ccl23/mpif-1, cf (25 ug) |
25 ug |
r&d systems |
| 3720-rg-050 |
recombinant human rgm-c, cf (50 ug) |
50 ug |
r&d systems |
| 3724-nr-050 |
recombinant mouse car/nr1i3/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 3725-rb-050 |
recombinant mouse activin riib/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 3726-ag-100 |
recombinant human agrp c-terminal fragment, cf (100 ug) |
100 ug |
r&d systems |
| 3727-bp-010 |
recombinant human bmp-4/bmp-7 heterodimer (10 ug) |
10 ug |
r&d systems |
| 3727-bp-010/cf |
recombinant human bmp-4/bmp-7 heterodimer, cf (10 ug) |
10 ug |
r&d systems |
| 3728-ng-050 |
recombinant rat nogo-a/fc chimera (aa 1026-1090), cf (50 ug) |
50 ug |
r&d systems |
| 372-ri-050 |
recombinant human tnf ri/tnfrsf1a/fc chimera (50 ug) |
50 ug |
r&d systems |
| 372-ri-050/cf |
recombinant human tnf ri/tnfrsf1a/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 3735-nt-050 |
recombinant human notch-2/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 373-tc-050 |
recombinant human trkc/fc chimera (50 ug) |
50 ug |
r&d systems |
| 373-tc-050/cf |
recombinant human trkc/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 3747-cl-025 |
recombinant canine il-1 beta/il-1f2 (25 ug) |
25 ug |
r&d systems |
| 3747-cl-025/cf |
recombinant canine il-1 beta/il-1f2, cf (25 ug) |
25 ug |
r&d systems |
| 374-ea-200 |
recombinant human ephrin-a5/fc chimera, cf (200 ug) |
200 ug |
r&d systems |
| 375-tec-010 |
recombinant human trail/tnfsf10 (e. coli-expressed) (10 ug) |
10 ug |
r&d systems |
| 375-tec-010/cf |
recombinant human trail/tnfsf10 (e. coli-expressed), cf (10 ug) |
10 ug |
r&d systems |
| 375-tl-010 |
recombinant human trail/tnfsf10 (10 ug) |
10 ug |
r&d systems |
| 375-tl-010/cf |
recombinant human trail/tnfsf10, cf (10 ug) |
10 ug |
r&d systems |
| 376-ct-025 |
recombinant human ccl27/ctack (25 ug) |
25 ug |
r&d systems |
| 376-ct-025/cf |
recombinant human ccl27/ctack, cf (25 ug) |
25 ug |
r&d systems |
| 3777-fk-100 |
recombinant human fkbp12, cf (100 ug) |
100 ug |
r&d systems |
| 377-hb-050 |
recombinant human nrg1-beta 1/hrg1-beta 1 ecd (50 ug) |
50 ug |
r&d systems |
| 377-hb-050/cf |
recombinant human nrg1-beta 1/hrg1-beta 1 ecd, cf (50 ug) |
50 ug |
r&d systems |
| 3780-ps-050 |
recombinant human psp94, cf (50 ug) |
50 ug |
r&d systems |
| 378-sm-025 |
recombinant human nrg1 isoform smdf (25 ug) |
25 ug |
r&d systems |
| 378-sm-025/cf |
recombinant human nrg1 isoform smdf, cf (25 ug) |
25 ug |
r&d systems |
| 3795-zn-020 |
recombinant human methionine aminopeptidase 2, cf (20 ug) |
20 ug |
r&d systems |
| 3796-se-010 |
recombinant human tryptase beta-2, cf (10 ug) |
10 ug |
r&d systems |
| 3814-zn-010 |
recombinant human neurolysin, cf (10 ug) |
10 ug |
r&d systems |
| 3815-zn-010 |
recombinant human aminopeptidase n/anpep, cf (10 ug) |
10 ug |
r&d systems |
| 3816-ce-010 |
recombinant canine erythropoietin (10 ug) |
10 ug |
r&d systems |
| 3816-ce-010/cf |
recombinant canine erythropoietin, cf (10 ug) |
10 ug |
r&d systems |
| 3817-av-050 |
recombinant human integrin alpha v beta 6, cf (50 ug) |
50 ug |
r&d systems |
| 3818-mr-050 |
recombinant mouse m-csf r/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 3819-fr-025 |
recombinant feline ccl5/rantes (25 ug) |
25 ug |
r&d systems |
| 3819-fr-025/cf |
recombinant feline ccl5/rantes, cf (25 ug) |
25 ug |
r&d systems |
| 381-gr-050 |
recombinant human g-csf sr/cd114 (50 ug) |
50 ug |
r&d systems |
| 381-gr-050/cf |
recombinant human g-csf sr/cd114, cf (50 ug) |
50 ug |
r&d systems |
| 3820-mr-025 |
recombinant mouse reelin |
25 µg |
r&d systems |
| 3820-mr-025 |
recombinant mouse reelin (25 ug) |
25 ug |
r&d systems |
| 3820-mr-025/cf |
recombinant mouse reelin, cf |
25 µg |
r&d systems |
| 3820-mr-025/cf |
recombinant mouse reelin, cf (25 ug) |
25 ug |
r&d systems |
| 3829-an-050 |
recombinant human angiopoietin-like 3, cf |
50 µg |
r&d systems |
| 382-cd-100 |
recombinant human cd27/tnfrsf7/fc chimera, cf (100 ug) |
100 ug |
r&d systems |
| 3830-zn-010 |
recombinant human aminopeptidase lrap/erap2, cf (10 ug) |
10 ug |
r&d systems |
| 383-cd-050 |
recombinant human cd14 (50 ug) |
50 ug |
r&d systems |
| 383-cd-050/cf |
recombinant human cd14, cf (50 ug) |
50 ug |
r&d systems |
| 3845-f5-050 |
recombinant human complement factor h-related 5/cfhr5, cf |
50 µg |
r&d systems |
| 3845-f5-050 |
recombinant human complement factor h-related 5/cfhr5, cf (50 ug) |
50 ug |
r&d systems |
| 3848-se-010 |
recombinant human trypsin 1/prss1, cf (10 ug) |
10 ug |
r&d systems |
| 384-rg-050 |
recombinant human common gamma chain (50 ug) |
50 ug |
r&d systems |
| 384-rg-050/cf |
recombinant human common gamma chain, cf (50 ug) |
50 ug |
r&d systems |
| 385-pr-100 |
recombinant human pdgf r beta/fc chimera (100 ug) |
100 ug |
r&d systems |
| 385-pr-100/cf |
recombinant human pdgf r beta/fc chimera, cf (100 ug) |
100 ug |
r&d systems |
| 3865-tr-050 |
recombinant human tenascin r, cf |
50 µg |
r&d systems |
| 3865-tr-050 |
recombinant human tenascin r, cf (50 ug) |
50 ug |
r&d systems |
| 3867-fg-025 |
recombinant human fgf-22 (25 ug) |
25 ug |
r&d systems |
| 3867-fg-025/cf |
recombinant human fgf-22, cf (25 ug) |
25 ug |
r&d systems |
| 3868-av-050 |
recombinant human integrin alpha l beta 2, cf (50 ug) |
50 ug |
r&d systems |
| 3870-n1-025 |
recombinant human neuropilin-1, cf (25 ug) |
25 ug |
r&d systems |
| 3874-t2-100 |
recombinant rat tie-2/fc chimera, cf (100 ug) |
100 ug |
r&d systems |
| 387-ne-025 |
recombinant human neurturin (histidine-tagged) (25 ug) |
25 ug |
r&d systems |
| 387-ne-025/cf |
recombinant human neurturin (histidine-tagged), cf (25 ug) |
25 ug |
r&d systems |
| 3894-pa-010 |
recombinant mouse thrombomodulin/cd141, cf |
10 µg |
r&d systems |
| 389-lr-100 |
recombinant human leptin r/fc chimera (100 ug) |
100 ug |
r&d systems |
| 389-lr-100/cf |
recombinant human leptin r/fc chimera, cf (100 ug) |
100 ug |
r&d systems |
| 390-tn-010 |
recombinant human trance/rank l/tnfsf11 (truncated) (10 ug) |
10 ug |
r&d systems |
| 390-tn-010/cf |
recombinant human trance/rank l/tnfsf11 (truncated), cf (10 ug) |
10 ug |
r&d systems |
| 391-gr-050 |
recombinant human igf-i sr,(igf-1 sr), cf (50 ug) |
50 ug |
r&d systems |
| 392-mg-010 |
recombinant human cxcl9/mig (10 ug) |
10 ug |
r&d systems |
| 392-mg-010/cf |
recombinant human cxcl9/mig, cf (10 ug) |
10 ug |
r&d systems |
| 392-mg-050 |
recombinant human cxcl9/mig (50 ug) |
50 ug |
r&d systems |
| 392-mg-050/cf |
recombinant human cxcl9/mig, cf (50 ug) |
50 ug |
r&d systems |
| 3934-cm-050 |
recombinant human ceacam-6/cd66c, cf (50 ug) |
50 ug |
r&d systems |
| 3937-ec-050 |
recombinant human ecm-1, cf (50 ug) |
50 ug |
r&d systems |
| 3938-fn-050 |
recombinant human fibronectin fragment 3, cf (50 ug) |
50 ug |
r&d systems |
| 3939-fa-050 |
recombinant human fcar/cd89, cf (50 ug) |
50 ug |
r&d systems |
| 393-np-010 |
recombinant human cxcl7/nap-2 (10 ug) |
10 ug |
r&d systems |
| 393-np-010/cf |
recombinant human cxcl7/nap-2, cf (10 ug) |
10 ug |
r&d systems |
| 393-np-050 |
recombinant human cxcl7/nap-2 (50 ug) |
50 ug |
r&d systems |
| 393-np-050/cf |
recombinant human cxcl7/nap-2, cf (50 ug) |
50 ug |
r&d systems |
| 3940-ts-050 |
recombinant human tsk, cf (50 ug) |
50 ug |
r&d systems |
| 3944-ed-010 |
recombinant human ectodysplasin (eda) (10 ug) |
10 ug |
r&d systems |
| 3944-ed-010/cf |
recombinant human ectodysplasin (eda), cf (10 ug) |
10 ug |
r&d systems |
| 3946-se-010 |
recombinant human matriptase/st14 catalytic domain, cf (10 ug) |
10 ug |
r&d systems |
| 3947-pa-010 |
recombinant human thrombomodulin/cd141, cf (10 ug) |
10 ug |
r&d systems |
| 3948-ap-010 |
recombinant human tracp/pap/acp5, cf (10 ug) |
10 ug |
r&d systems |
| 394-pa-010 |
recombinant human ccl18/parc (10 ug) |
10 ug |
r&d systems |
| 394-pa-010/cf |
recombinant human ccl18/parc, cf (10 ug) |
10 ug |
r&d systems |
| 394-pa-050 |
recombinant human ccl18/parc (50 ug) |
50 ug |
r&d systems |
| 394-pa-050/cf |
recombinant human ccl18/parc, cf (50 ug) |
50 ug |
r&d systems |
| 3956-bp-050 |
recombinant human bmp-10 propeptide, cf |
50 µg |
r&d systems |
| 395-eb-200 |
recombinant human ephrin-b3/fc chimera, cf (200 ug) |
200 ug |
r&d systems |
| 3968-cd-050 |
recombinant human cd99/fc chimera, cf |
50 µg |
r&d systems |
| 396-hb-050 |
recombinant human nrg1-beta 1/hrg1-beta 1 egf domain (50 ug) |
50 ug |
r&d systems |
| 396-hb-050/cf |
recombinant human nrg1-beta 1/hrg1-beta 1 egf domain, cf (50 ug) |
50 ug |
r&d systems |
| 397-tr-050 |
recombinant human trkb (50 ug) |
50 ug |
r&d systems |
| 397-tr-050/cf |
recombinant human trkb, cf (50 ug) |
50 ug |
r&d systems |
| 3986-nt-050 |
recombinant mouse ntb-a/slamf6, cf |
50 µg |
r&d systems |
| 3986-nt-050 |
recombinant mouse ntb-a/slamf6, cf (50 ug) |
50 ug |
r&d systems |
| 398-lp-01m |
recombinant human leptin, cf (1 mg) |
1 mg |
r&d systems |
| 398-lp-05m |
recombinant human leptin, cf (5 mg) |
5 mg |
r&d systems |
| 4007-zn-010 |
recombinant mouse meprin alpha subunit/mep1a, cf (10 ug) |
10 ug |
r&d systems |
| 4008-zn-010 |
recombinant human leukotriene a4 hydrolase/lta4h, cf (10 ug) |
10 ug |
r&d systems |
| 4009-bc-050 |
recombinant human brevican, cf |
50 µg |
r&d systems |
| 400-ml-005 |
recombinant mouse il-1 alpha/il-1f1 (5 ug) |
5 ug |
r&d systems |
| 400-ml-005/cf |
recombinant mouse il-1 alpha/il-1f1, cf (5 ug) |
5 ug |
r&d systems |
| 400-ml-025 |
recombinant mouse il-1 alpha/il-1f1 (25 ug) |
25 ug |
r&d systems |
| 400-ml-025/cf |
recombinant mouse il-1 alpha/il-1f1, cf (25 ug) |
25 ug |
r&d systems |
| 4010-dk-010 |
recombinant rat dkk-1 (10 ug) |
10 ug |
r&d systems |
| 4010-dk-010/cf |
recombinant rat dkk-1, cf (10 ug) |
10 ug |
r&d systems |
| 4014-sp-050 |
recombinant human ibsp/sialoprotein ii, cf (50 ug) |
50 ug |
r&d systems |
| 4015-ab-050 |
recombinant human ifn-alpha/beta r2/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 4016-lr-050 |
recombinant mouse lair1, cf (50 ug) |
50 ug |
r&d systems |
| 4017-tr-025 |
recombinant canine stnf ri/tnfrsf1a |
25 µg |
r&d systems |
| 4017-tr-025/cf |
recombinant canine stnf ri/tnfrsf1a, cf |
25 µg |
r&d systems |
| 4017-tr-050 |
recombinant canine stnf ri/tnfrsf1a (50 ug) |
50 ug |
r&d systems |
| 4017-tr-050/cf |
recombinant canine stnf ri/tnfrsf1a, cf (50 ug) |
50 ug |
r&d systems |
| 401-ml-005 |
recombinant mouse il-1 beta/il-1f2 (5 ug) |
5 ug |
r&d systems |
| 401-ml-005/cf |
recombinant mouse il-1 beta/il-1f2, cf (5 ug) |
5 ug |
r&d systems |
| 401-ml-025 |
recombinant mouse il-1 beta/il-1f2 (25 ug) |
25 ug |
r&d systems |
| 401-ml-025/cf |
recombinant mouse il-1 beta/il-1f2, cf (25 ug) |
25 ug |
r&d systems |
| 402-ml-020 |
recombinant mouse il-2 (20 ug) |
20 ug |
r&d systems |
| 402-ml-020/cf |
recombinant mouse il-2, cf (20 ug) |
20 ug |
r&d systems |
| 402-ml-100 |
recombinant mouse il-2 (100 ug) |
100 ug |
r&d systems |
| 402-ml-100/cf |
recombinant mouse il-2, cf (100 ug) |
100 ug |
r&d systems |
| 403-ml-010 |
recombinant mouse il-3 (10 ug) |
10 ug |
r&d systems |
| 403-ml-010/cf |
recombinant mouse il-3, cf (10 ug) |
10 ug |
r&d systems |
| 403-ml-050 |
recombinant mouse il-3 (50 ug) |
50 ug |
r&d systems |
| 403-ml-050/cf |
recombinant mouse il-3, cf (50 ug) |
50 ug |
r&d systems |
| 4047-am-050 |
recombinant human integrin alpha m beta 2, cf (50 ug) |
50 ug |
r&d systems |
| 404-ml-010 |
recombinant mouse il-4 (10 ug) |
10 ug |
r&d systems |
| 404-ml-010/cf |
recombinant mouse il-4, cf (10 ug) |
10 ug |
r&d systems |
| 404-ml-050 |
recombinant mouse il-4 (50 ug) |
50 ug |
r&d systems |
| 404-ml-050/cf |
recombinant mouse il-4, cf (50 ug) |
50 ug |
r&d systems |
| 405-ml-005 |
recombinant mouse il-5 (5 ug) |
5 ug |
r&d systems |
| 405-ml-005/cf |
recombinant mouse il-5, cf (5 ug) |
5 ug |
r&d systems |
| 405-ml-025 |
recombinant mouse il-5 (25 ug) |
25 ug |
r&d systems |
| 405-ml-025/cf |
recombinant mouse il-5, cf (25 ug) |
25 ug |
r&d systems |
| 4067-gp-050 |
recombinant human gpib alpha, cf |
50 µg |
r&d systems |
| 406-ml-005 |
recombinant mouse il-6 (5 ug) |
5 ug |
r&d systems |
| 406-ml-005/cf |
recombinant mouse il-6, cf (5 ug) |
5 ug |
r&d systems |
| 406-ml-025 |
recombinant mouse il-6 (25 ug) |
25 ug |
r&d systems |
| 406-ml-025/cf |
recombinant mouse il-6, cf (25 ug) |
25 ug |
r&d systems |
| 407-ml-005 |
recombinant mouse il-7 (5 ug) |
5 ug |
r&d systems |
| 407-ml-005/cf |
recombinant mouse il-7, cf (5 ug) |
5 ug |
r&d systems |
| 407-ml-025 |
recombinant mouse il-7 (25 ug) |
25 ug |
r&d systems |
| 407-ml-025/cf |
recombinant mouse il-7, cf (25 ug) |
25 ug |
r&d systems |
| 4090-as-020 |
recombinant human renin, cf (20 ug) |
20 ug |
r&d systems |
| 4095-eg-025 |
recombinant mouse pro-egf (aa 1-1029) (25 ug) |
25 ug |
r&d systems |
| 4095-eg-025/cf |
recombinant mouse pro-egf (aa 1-1029), cf (25 ug) |
25 ug |
r&d systems |
| 4096-mc-050 |
recombinant human m-cadherin/fc chimera, cf (50 ug) |
50 ug |
r&d systems |
| 4099-se-010 |
recombinant human chymase/cma1, cf |
10 µg |
r&d systems |
| 4099-se-010 |
recombinant human chymase/cma1, cf (10 ug) |
10 ug |
r&d systems |
| 409-ml-010 |
recombinant mouse il-9 (10 ug) |
10 ug |
r&d systems |
| 409-ml-010/cf |
recombinant mouse il-9, cf (10 ug) |
10 ug |
r&d systems |
| 409-ml-050 |
recombinant mouse il-9 (50 ug) |
50 ug |
r&d systems |
| 409-ml-050/cf |
recombinant mouse il-9, cf (50 ug) |
50 ug |
r&d systems |
| 410-mt-010/cf |
recombinant mouse tnf-alpha/tnfsf1a, cf (10 ug) |
10 ug |
r&d systems |
| 410-mt-050/cf |
recombinant mouse tnf-alpha/tnfsf1a, cf (50 ug) |
50 ug |
r&d systems |
| 410-trnc-010 |
recombinant mouse tnf-alpha/tnfsf1a, truncated form (10 ug) |
10 ug |
r&d systems |
| 410-trnc-010/cf |
recombinant mouse tnf-alpha/tnfsf1a, truncated form, cf (10 ug) |
10 ug |
r&d systems |
| 410-trnc-050 |
recombinant mouse tnf-alpha/tnfsf1a, truncated form (50 ug) |
50 ug |
r&d systems |
| 410-trnc-050/cf |
recombinant mouse tnf-alpha/tnfsf1a, truncated form, cf (50 ug) |
50 ug |
r&d systems |
| 4114-tc-01m |
recombinant human fgf basic, 145 aa (tc grade), cf |
1 mg |
r&d systems |
| 4114-tc-01m |
recombinant human fgf-basic, 145 aa (tissue culture grade) (1 mg) |
1 mg |
r&d systems |
| 4119-gh-010 |
recombinant human alpha-l-iduronidase/idua, cf (10 ug) |
10 ug |
r&d systems |
| 4128-cm-050 |
recombinant human ceacam-5, cf |
50 µg |
r&d systems |
| 4129-dm-050 |
recombinant human dmp-1, cf |
50 µg |
r&d systems |
| 4129-dm-050 |
recombinant human dmp-1, cf (50 ug) |
50 ug |
r&d systems |
| 4134-rl-010 |
recombinant rat il-9 |
10 µg |
r&d systems |
| 4134-rl-010 |
recombinant rat il-9 (10 ug) |
10 ug |
r&d systems |
| 4134-rl-010/cf |
recombinant rat il-9, cf |
10 µg |
r&d systems |
| 4134-rl-010/cf |
recombinant rat il-9, cf (10 ug) |
10 ug |
r&d systems |
| 4135-av-050 |
recombinant human integrin alpha v beta 8, cf (50 ug) |
50 ug |
r&d systems |
| 4136-kr-050 |
recombinant human kir3ds1/fc chimera,cf (50 ug) |
50 ug |
r&d systems |
| 4137-s4-050 |
recombinant human s100a4, cf |
50 µg |
r&d systems |
| 4137-s4-050 |
recombinant human s100a4, cf (50 ug) |
50 ug |
r&d systems |
| 4138-s4-050 |
recombinant mouse s100a4, cf |
50 µg |
r&d systems |
| 4138-s4-050 |
recombinant mouse s100a4, cf (50 ug) |
50 ug |
r&d systems |
| 4139-se-010 |
recombinant bovine enteropeptidase/enterokinase, cf (10 ug) |
10 ug |
r&d systems |
| 413-ml-005 |
recombinant mouse il-13 (5 ug) |
5 ug |
r&d systems |
| 413-ml-005/cf |
recombinant mouse il-13, cf (5 ug) |
5 ug |
r&d systems |
| r&d systems 产品目录列表 page 4 >> 1 2 3 4 5 6 7 8 9 10 >>..more |
400 8700 545
400 8700 545
